SCHEMBL6798162

SCHEMBL6798162

O=c1c2cc(F)c(F)cc2n(-c2cc(F)c(F)cc2F)c(=O)n1OCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.41
TSHR P16473 2/20 0.41
ALOX15 P16050 1/20 0.39
KDM4E B2RXH2 3/20 0.36
HBB P68871 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CTSV O60911 2/20 0.35
CTSL P07711 2/20 0.35
NPSR1 Q6W5P4 1/20 0.33
MEN1 O00255 1/20 0.32
POLB P06746 1/20 0.32
HPGD P15428 1/20 0.32
KMT2A Q03164 1/20 0.32
TP53 P04637 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
MAPT P10636 1/20 0.32
MAOB P27338 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6800550 0.92 ALDH1A1 (0.42) ALDH1A1TSHRALOX15KDM4EHBB
SCHEMBL6799569 0.90 GLA (0.41) ALDH1A1TSHRALOX15KDM4EHBB
SCHEMBL6801065 0.85 ALDH1A1 (0.41) ALDH1A1TSHRALOX15KDM4EHBB
SCHEMBL6796203 0.84 ALDH1A1 (0.40) ALDH1A1TSHRALOX15KDM4EHBB
SCHEMBL6802703 0.83 ALDH1A1 (0.41) ALDH1A1TSHRALOX15KDM4EL3MBTL1
SCHEMBL6801037 0.82 THRB (0.41) ALDH1A1TSHRMEN1POLBKMT2A
SCHEMBL6795932 0.81 ALDH1A1 (0.47) ALDH1A1TSHRALOX15KDM4EHBB
SCHEMBL6801629 0.81 MAPT (0.41) ALDH1A1TSHRALOX15KDM4ETP53
SCHEMBL6799704 0.80 GNRHR (0.44) POLBTP53MAPTMAOBMAPK8
SCHEMBL6797135 0.80 ALDH1A1 (0.48) ALDH1A1TSHRALOX15KDM4EHBB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP claimed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US claimed
EP-1028950-A1 NOVEL 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 2000-08-23 EP claimed
WO-1999021840-A1 NOVEL 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 1999-05-06 WO claimed
US-6825199-B2 7-Substituted quinazolin-2,4-diones useful as antibacterial agents WARNER-LAMBERT COMPANY 2004-11-30 US disclosed
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP disclosed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US disclosed
US-6331538-B1 TREATMENT OF BACTERIAL INFECTION WARNER-LAMBERT COMPANY 2001-12-18 US disclosed
EP-1028950-A1 NOVEL 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 2000-08-23 EP disclosed
WO-1999021840-A1 NOVEL 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents NQO2, TOP1, TOP2A ALDH1A1 3064/4885TSHR 4720/4885ALOX15 4414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.